The occurrence of ventricular fibrillation (VF) is dependent on the deterioration of channelopathy in the myocardium. It is interesting to investigate molecular changes in relation to abrupt appearance of VF on reperfusion. We aimed to study whether changes in the expression of FKBP12.6 and SERCA2a and the endothelin (ET) system on reperfusion against ischemia were related to the rapid occurrence of VF and whether CPU86017, a class III antiarrhythmic agent which blocks IKr, IKs, and ICa.L, suppressed VF by correcting the molecular changes on reperfusion.
Cardiomyopathy (CM) was produced by 0.4 mg/kg sc L-thyroxin for 10 d in rats, and subjected to 10 min coronary artery ligation/reperfusion on d 11. Expressions of the Ca2+ handling and ET system and calcium transients were conducted and CPU86017 was injected (4 mg/kg, sc) on d 6–10.
A high incidence of VF was found on reperfusion of the rat CM hearts, but there was no VF before reperfusion. The elevation of diastolic calcium was significant in the CM myocytes and exhibited abnormality of the Ca2+ handling system. The rapid downregulation of mRNA and the protein expression of FKBP12.6 and SERCA2a were found on reperfusion in association with the upregulation of the expression of the endothelin-converting enzyme (ECE) and protein kinase A (PKA), in contrast, no change in the ryanodine type 2 receptor (RyR2), phospholamban (PLB), endothelin A receptor (ETAR), and iNOS was found. CPU86017 removed these changes and suppressed VF.
Abrupt changes in the expression of FKBP12.6, SERCA2a, PKA, and ECE on reperfusion against ischemia, which are responsible for the rapid occurrence of VF, have been observed. These changes are effectively prevented by CPU86017.
Roberts R, Brugada R . Genetics and arrhythmias. Annu Rev Med, 2003; 54: 257–67.
Dai DZ, Yu F . Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias. Acta Pharmacol Sin, 2005; 26: 918–25.
Rubart M, Zipes DP . Mechanisms of sudden cardiac death. J Clin Invest, 2005; 115: 2305–15.
Sen-Chowdhry S, McKenna WJ . Sudden cardiac death in the young: a strategy for prevention by targeted evaluation. Cardiology, 2006; 105: 196–206.
Schwartz PJ . Management of long QT syndrome. Nat Clin Pract Cardiovasc Med, 2005; 2: 346–51.
Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ . Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc, 2004; 79: 1380–4.
Olson EN . A decade of discoveries in cardiac biology. Nat Med, 2004; 10: 467–74.
Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell, 2003; 113: 829–40.
Dai DZ . Two patterns of ion channelopathy in the myocardium: perspectives for development of anti-arrhythmic agents. Curr Opin Investig Drugs, 2005; 6: 289–97.
Yu F, Dai DZ, An LF, Guo XF . Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Acta Pharmacol Sin, 1997; 18: 71–4.
Dai DZ, Hu HJ, Yang DM, Hao XM, Zhang GQ, Zhou PA, et al. Chronic levothyroxin treatment is associated with ion channel abnormalities in cardiac and neuronal cells. Clin Exp Pharmacol Physiol, 1999; 26: 819–21.
Wang HL, Li SB, Dai DZ . Change on L-type calcium current in single guinea pig hypertrophic ventricular myocytes induced by levothyroxine. J China Pharm Univ, 2000; 31: 130–4.
Zhang GQ, Hao XM, Ma YP, Zhou PA, Wu CH, Dai DZ . Characteristics of the delayed rectifier K+ current in guinea pig hypertrophied ventricular myocytes induced by thyroxin. China Pharmacol Bull, 2001; 17: 174–7.
Zhang GQ, Ma YP, Hao XM, Zhou PA, Wu CH, Dai DZ . Rapidly activating delayed rectifier K+ current and inward rectifier K+ current in cardiomyocytes from hypertrophied guinea pig hearts induced by thyroxine. J China Pharm Univ, 2000; 31: 451–4.
Brugada R, Hong K, Cordeiro JM, Dumaine R . Short QT syndrome. CMAJ, 2005; 173: 1349–54.
Xia HJ, Dai DZ, Dai Y . Up-regulated inflammatory factors endothelin, NF?B, TNF-α and iNOS involved in exaggerated cardiac arrhythmias in L-thyroxin induced cardiomyopathy are suppressed by darusentan in rats. Life Sci, 2006; 79: 1812–9.
Dai DZ . CPU86017: a novel class III antiarrhythmic agent with multiple actions at ion channels. Cardiovasc Drug Rev, 2006; 24: 100–14.
Kao JP, Harootunian AT, Tsien RY . Photochemically generated cytosolic calcium pulses and their detection by Fluo-3. J Biol Chem, 1989; 264: 8179–84.
Virag L, Scott GS, Antal-Szalmas P, O'Connor M, Ohshima H, Szabo C . Requirement of intracellular calcium mobilization for peroxynitrite-induced poly(ADP-ribose) synthetase activation and cytotoxicity. Mol Pharmacol, 1999; 56: 824–33.
Qi MY, Xia HJ, Dai DZ, Dai Y . A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a and PLB in rats. J Cardiovasc Pharmacol, 2006; 47: 729–35.
Katra RP, Laurita KR . Cellular mechanism of calcium-mediated triggered activity in the heart. Circ Res, 2005; 96: 535–42.
Wehrens XH, Marks AR . Sudden unexplained death caused by cardiac ryanodine receptor (RyR2) mutations. Mayo Clin Proc, 2004; 79: 1367–71.
Wu XD, Dai DZ, Zhang QP, Gao F . Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in L-thyroxin-induced rat ventricular hypertrophy. Acta Pharmacol Sin, 2004; 25: 347–51.
Wang YQ, Shi YP, Dai DZ . Therapeutic effects of CPU 86017 on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats. Drug Dev Res, 2004; 63: 22–32.
Ligeti L, Szenczi O, Prestia CM, Szabo C, Horvath K, Marcsek ZL, et al. Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy. Int J Mol Med, 2006; 17: 1035–43.
Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS, et al. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun, 2002; 291: 433–8.
Jeyakumar LH, Ballester L, Cheng DS, McIntyre JO, Chang P, Olivey HE, et al. FKBP binding characteristics of cardiac microsomes from diverse vertebrates. Biochem Biophys Res Commun, 2001; 281: 979–86.
Miyauchi T, Masaki T . Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol, 1999; 61: 391–415.
Xu FP, Chen MS, Wang YZ, Yi Q, Lin SB, Chen AF, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation, 2004; 110: 1269–75.
Temsah RM, Netticadan T, Chapman D, Takeda S, Mochizuki S, Dhalla NS . Alterations in sarcoplasmic reticulum function and gene expression in ischemic-reperfused rat heart. Am J Physiol, 1999; 277: H584–94.
Gupta SK, Saxena A, Singh U, Arya DS . Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. Mol Cell Biochem, 2005; 275: 67–74.
Hao JM, Dai DZ, Yu F . The oxidative stress enhancing effects by L-thyroxin and the antioxidant effects of CPU 86017, a derivative of tetrahydroberberine. Prog Pharmaceut Sci, 2005; 29: 417–21.
Nakaya H, Furusawa Y, Ogura T, Tamagawa M, Uemura H . Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts. Br J Pharmacol, 2000; 131: 1363–72.
Kohno M, Yano M, Kobayashi S, Doi M, Oda T, Tokuhisa T, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol, 2003; 284: H1035–42.
Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart, 2003; 89: 66–70.
Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M . Short QT syndrome. Cardiovasc Res, 2005; 67: 357–66.
Piccirillo G, Magri D, Matera S, Magnanti M, Torrini A, Pasquazzi E, et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study. Eur Heart J 2006 Nov 13; [Epub ahead of print].
Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation, 2004; 110: 2453–9.
Tomaselli GF, Zipes D P . What causes sudden death in heart failure? Circ Res 2004; 95: 754–63.
Gollob MH . Genetic profiling as a marker for risk of sudden cardiac death. Curr Opin Cardiol, 2006; 21: 42–6.
Chow BJ, Gollob M, Birnie D . Brugada syndrome precipitated by a tricyclic antidepressant. Heart, 2005; 91: 651.
Woo SH, Lee CO . Effects of endothelin-1 on Ca2+ signaling in guinea-pig ventricular myocytes: role of protein kinase C. J Mol Cell Cardiol, 1999; 31: 631–43.
Chen J, Mehta JL . Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol, 2006; 291: H1738–45.
Project supported by the National Natural Science Foundation of China (No 30572193 and 30230170).
About this article
Cite this article
Na, T., Huang, Zj., Dai, Dz. et al. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. Acta Pharmacol Sin 28, 773–782 (2007). https://doi.org/10.1111/j.1745-7254.2007.00580.x
- sudden cardiac death
- ventricular fibrillation endothelin
- protein kinase A
- endothelin-converting enzyme
Frontiers in Pharmacology (2020)
David Triggle: Research collaborations and scientific exchanges with the China Pharmaceutical University, Nanjing, China
Biochemical Pharmacology (2015)
CPU86017-RS attenuate hypoxia-induced testicular dysfunction in mice by normalizing androgen biosynthesis genes and pro-inflammatory cytokines
Acta Pharmacologica Sinica (2012)
Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue
Naunyn-Schmiedeberg's Archives of Pharmacology (2011)
CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity
Acta Pharmacologica Sinica (2010)